NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Lb Pharmaceuticals LBRX

Lb Pharmaceuticals listed on Nasdaq on 12 Sep 2025 and is not in the S&P 500. It is worth $1.3 billion. Its board has 10 directors, 7 of them independent. 3 other officers are on file. At 30 Jun 2026, Deep Track Capital was its largest institutional holder, with 11.7% of the company.

CEO
Heather D. Turner
Chair
J. Scott Garland
Listed
12 Sep 2025 on Nasdaq
Headquarters
New York, NY
Market cap
$1.3B
19 Nov 2026 close
Revenue
-
No annual report yet

Financials

Lb Pharmaceuticals' market cap since September 2025

Marked weeks are changes in the share count, such as a merger, not market moves.

Weekly, up to 13 Nov 2026

Nov 2025Jan 2026MarMayJulSepNov$1.4B

Board and leadership

Board and officers

Board from the proxy filed 23 Apr 2026; officers filed up to 30 Sep 2026

NameTitleSinceIndependentCommitteesAge
Directors (10)
J. Scott GarlandChairIndependent 路 since 2024 路 Audit, Compensation (chair)Advisor, Google VenturesOther boards: Enliven Therapeutics, Olema Pharmaceuticals, ALX Oncology and Day One BiopharmaceuticalsChair2024YesAudit, Compensation (chair)57
Heather D. TurnerDirector and CEONot independent 路 since 2024Other boards: Terns PharmaceuticalsDirector and CEO2024No53
Robert R. Ruffolo, Jr., Ph.D., D.Sc., D.Eng., F.C.P.P.DirectorIndependent 路 since 2019 路 AuditCorporate Director and Former President of Research and Development, Wyeth Pharmaceuticals, Inc.Other boards: Elicio TherapeuticsDirector2019YesAudit76
Rekha HemrajaniDirectorIndependent 路 since 2025 路 Audit (chair), CompensationCorporate DirectorOther boards: ALX Oncology Holdings, MaxCyte and BioAge LabsDirector2025YesAudit (chair), Compensation56
William P. Kane Jr.DirectorIndependent 路 since 2025 路 CompensationPresident and Chief Executive Officer, Uniquity Bio, Inc.Director2025YesCompensation64
Robert A. LenzDirectorDirector
Robert A. Lenz, M.D., Ph.D.DirectorIndependent 路 since 2026 路 Nominating and Corporate GovernanceBoard Member, NovaBridge BiosciencesOther boards: NovaBridge BiosciencesDirector2026YesNominating and Corporate Governance55
Rebecca LuseDirectorIndependent 路 since 2023 路 Nominating and Corporate Governance (chair)Managing Director of Deep Track CapitalDirector2023YesNominating and Corporate Governance (chair)41
Ran NussbaumDirectorIndependent 路 since 2023 路 Nominating and Corporate GovernanceManaging Partner and Co-Founder, PontifaxDirector2023YesNominating and Corporate Governance53
Robert R. RuffoloDirectorDirector
Officers (3)
Joseph M. MillerChief Financial OfficerLast filed 14 Sep 2026Chief Financial Officer
Susan Gani KozauerChief Medical OfficerLast filed 24 Sep 2026Chief Medical Officer
Panandiker Kaya Kamlesh PaiChief Commercial OfficerLast filed 11 Dec 2025Chief Commercial Officer

Owners and trading

Largest institutional holders

Each fund group's share of Lb Pharmaceuticals. Where a company has several share classes, the share is of its total value. Stakes are of the shares out at 30 Jun 2026; the count has since grown 13%.

13F filings for the quarter to 30 Jun 2026

  • Deep Track Capital11.7%
  • BlackRock9.5%
  • Ra Capital Management7.7%
  • Trails Edge Capital Partners5.3%
  • Commodore Capital5.2%

These five hold 39.5% of Lb Pharmaceuticals.

Timeline

Leadership changes, layoffs and insider sales

20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025

2 departures and 4 appointments of directors and officers in the last two years.

Left the company or board 2Appointed 4WARN layoff notices 0Jan 2025AprJulOctJan 2026AprJulOct

Events, newest first

Not on file: no open-market insider buys or sales in the 12 months to 19 Nov 2026, no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no quarterly results in its SEC XBRL filings.